The multivariable estimated relative odds of a GI AE were 13.4 ( 95 % CI , 3.44 to 52.3 ; P < .001 ) for IBD ; 2.05 ( 95 % CI , 1.09 to 3.88 ; P = .026 ) for LBR ; 1.95 ( 95 % CI , 0.894 to 4.25 ; P = .093 ) for SBR ; and 2.15 for bevacizumab exposure ( aggregated 95 % CI , 1.05 to 4.40 ; P = .036 ) .